Novartis moved to deepen its autoimmune pipeline with a major deal tied to Abogen’s in vivo engineered T-cell engager approach. The reported transaction structure includes a $7.8B agreement for Abogen’s platform, with in vivo targeting intended to reshape how CD targets and immune activation are delivered. The announcement signals continued pharma demand for next-generation immunology tools that can achieve potency while improving dosing convenience versus earlier ex vivo paradigms. It also suggests that large in vivo engager bets remain attractive even as the industry competes for differentiated engagement biology. For the biotech ecosystem, the size and early structure of the deal provide a reference point for valuations of translational immunoengineering platforms at pre- or mid-clinical stages.